$102 Million is the total value of VHCP Management, LLC's 24 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 50.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
CHRS | Sell | Coherus Biosciences Inc | $8,181,000 | -20.7% | 305,505 | -50.0% | 8.04% | -24.8% |
RGNX | Sell | REGENXBIO Inc | $337,000 | -19.8% | 24,089 | -54.1% | 0.33% | -23.9% |
GBT | Exit | Global Blood Therapeutics | $0 | – | -72,990 | -100.0% | -1.26% | – |
Exit | Cynapsus Therapeutics Inc | $0 | – | -108,575 | -100.0% | -1.87% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
DBV Technologies | 14 | Q4 2016 | 33.5% |
BioCryst Pharmaceuticals Inc | 13 | Q4 2016 | 11.9% |
Ocera Therapeutics | 13 | Q4 2016 | 4.9% |
Anacor Pharmaceuticals Inc | 12 | Q1 2016 | 35.6% |
Heron Therapeutics Inc | 12 | Q4 2016 | 20.5% |
Flamel Technologies S.A. | 12 | Q4 2016 | 6.1% |
GW Pharmaceuticals | 11 | Q4 2015 | 19.9% |
Lipocine Inc | 11 | Q4 2016 | 7.5% |
Stemline Therapeutics Inc | 11 | Q4 2016 | 1.7% |
Zafgen Inc | 10 | Q3 2016 | 5.7% |
View VHCP Management, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
4 | 2018-02-28 |
13F-HR | 2017-02-13 |
13F-HR | 2016-11-14 |
13F-HR | 2016-08-12 |
13F-HR | 2016-05-13 |
13F-HR | 2016-02-12 |
13F-HR | 2015-11-13 |
13F-HR | 2015-08-13 |
3 | 2015-06-17 |
13F-HR | 2015-05-14 |
View VHCP Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.